03:29pm Tuesday 19 November 2019

Study highlights the burden of epilepsy in low-income countries

The researchers call for greater recognition from international and national health agencies to address the management of epilepsy in low- and lower-middle-income countries.

Despite being one of the most cost-effective disorders to treat, there are twice as many people living with epilepsy in low- and lower-middle-income countries than higher income nations, and more than 60 per cent of those affected in these regions are not accessing any appropriate treatment.

Lead author Professor Charles Newton, who works in the Wellcome Trust programmes in Tanzania and Kenya, said: “Epilepsy needs to be brought into the agenda of non-communicable diseases. It was not mentioned in the UN General Assembly Meeting in New York to address the global burden of non-communicable diseases, and yet it represents a substantial burden of ill health.”

Epilepsy is a common disorder, particularly in poor areas of the world, but deriving accurate figures on the epidemiology of epilepsy in low- and lower-middle-income countries is very difficult. There have been very few surveys to gather appropriate data, and such studies tend to be expensive, especially for countries whose health research funding is likely to be very limited.

Professor Newton and Professor Hector Garcia, both Wellcome Trust Senior Research Fellows, conducted a comprehensive review of academic articles about epilepsy in low-income countries to piece together a picture of the burden of the disease in poorer parts of the world.

They conclude that the high number of people with epilepsy in these regions is probably caused by the higher incidence of risk factors, such as head trauma, complications during childbirth, and parasite infections such as pork tapeworm (neurocysticercosis), and river blindness (onchocerciasis).

The study also reveals the enormity of the treatment gap in poorer nations, with more than 60 per cent of people living with epilepsy in low- and lower-middle-income countries not accessing appropriate care. This is partly because of poor adherence to prescribed treatment, but huge barriers to accessing care remain, particularly in rural areas.

The stigma associated with the disorder and cultural beliefs around causation have been identified as major problems, along with distance from a healthcare facility and inadequate skilled manpower.

The epilepsy burden could be easily reduced by addressing some of the risk factors, say the authors of the study. They highlight several ways in which epilepsy care could be improved at low cost, including engaging traditional healers who for many people are the only point of care for epilepsy. Given the lack of expertise in management of epilepsy in poorer areas, they suggest that neurologists and psychiatrists should combine to set up services for the management of epilepsy in these regions.

“Sadly, adequate facilities for diagnosis, treatment and ongoing management of epilepsy are virtually non-existent in many of the world’s poorest regions. Many people with epilepsy or their families do not even know that they have a disorder that can be controlled with biomedical treatment, so it is vitally important that awareness is raised and medical care improved in these regions,” added Professor Newton.

The review is published today in the ‘Lancet’ series on epilepsy.

Image: A digitally enhanced MRI of the human head showing the brain and spinal cord in blue and green and other tissues in red and pink. Credit: Mark Lythgoe and Chloe Hutton, Wellcome Images.


Jen Middleton
Senior Media Officer, Wellcome Trust
+44 20 7611 7262

Notes to editors

Newton CR and Garcia HH. Epilepsy in poor regions of the world. Lancet 2012 (epub ahead of print).

About the KEMRI-Wellcome Trust Research Programme
The KEMRI-Wellcome Trust Research Programme is well known internationally for its work tackling malaria and other infectious diseases, particularly bacterial and viral childhood infections. With links to the Trust since the 1940s, the Programme was formally established in 1989, in partnership with the Kenya Medical Research Institute (KEMRI). It conducts basic and clinical research in parallel, with results feeding directly into local and international health policy, and aims to expand the country’s capacity to conduct multidisciplinary research that is strong, sustainable and internationally competitive.

About the Wellcome Trust
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust’s breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests.

Share on:

MORE FROM Brain and Nerves

Health news